PILOT TRIAL OF TC SESTAMIBI WITH CYCLOSPORINE A AND VINBLASTINE IN CANCER

TC Sestamibi 与环孢菌素 A 和长春花碱治疗癌症的试点试验

• 批准号: 5218376
• 负责人: DAVID SMITH
• 金额: --
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/5218376
• 关键词: P glycoprotein; clinical research; combination chemotherapy; cyclosporines; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; neoplasm /cancer radionuclide diagnosis; pharmacokinetics; radionuclide imaging /scanning; radiotracer; technetium; vinblastine

This is a feasibility study using TcSESTAMIBI, a technetium labelled probe that has potential to identify p-glycoprotein pump activity. It is being evaluated as an indicator of an alteration in "in vivo" P-glycoprotein function. Cyclosporine is an inhibitor of this pump and will be tested alone and in combination with vinblastine in patients with tumors known to have increased levels of P-glycoprotein. Additionally, this study seeks to establish a method to quantify uptake of TcSESTAMIBI in tumor an normal tissues so that valid and reliable comparisons can be made.

这是一项使用TcSESTAMIBI的可行性研究， 具有鉴定P-糖蛋白泵活性潜力的探针。 它 被评估为“体内”改变的指标 P-糖蛋白功能。环孢菌素是该泵的抑制剂， 将在以下患者中单独测试以及与长春碱联合测试 已知具有增加的P-糖蛋白水平的肿瘤。 此外，本发明还 本研究旨在建立一种定量TcSESTAMIBI摄取的方法 在肿瘤和正常组织中进行有效和可靠的比较， 进行了